6月15日，康方生物盘中下跌3.04%，报89.2港元，成交额13.48亿港元。此前公司董事会批准最多2亿港元回购计划曾短暂提振股价，但ASCO利好兑现后的持续抛压再度主导走势。
消息面上，公司核心产品依沃西HARMONi-6研究OS阳性结果于6月1日ASCO全体会议公布后，事件驱动型资金持续获利了结，叠加美方可能限制对中国生物技术投资的传闻扰动及市场对创新药盈利能力的担忧，板块整体承压。尽管多家券商维持买入评级，资金面抛压仍主导短线走势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.